Celularity Inc. Faces Nasdaq Listing Challenges
Recently, Celularity Inc., a pioneering regenerative medicine company primarily focused on placental-derived technologies, announced an important update regarding its Nasdaq listing. The company, which trades under the ticker symbols "CELU" for its common stock and "CELUW" for its warrants, received a formal notice from the Listing Qualifications department of Nasdaq Stock Market LLC. This notice, which was dated October 16, 2024, reveals that the company is at risk of delisting due to its failure to timely file its Forms 10-Q for the periods ending March 31 and June 30, 2024.
Reasons Behind Nasdaq's Delisting Notice
While this notice presents a significant hurdle, it is vital to note that there is no immediate effect on the trading of Celularity's stock and warrants. These securities continue to trade on the Nasdaq Capital Market. The company plans to appeal the delisting determination by engaging with the Nasdaq Hearings Panel and is expected to submit its appeal before October 24, 2024. The appeal will include arguments centered around a strategy to resume compliance with Nasdaq's listing requirements.
The Company’s Commitment to Compliance
Celularity has filed its annual report on Form 10-K for the fiscal year 2023 within the compliance time frame. Furthermore, it has submitted its quarterly report for the first quarter of 2024 on October 16, 2024. The second quarter's 10-Q is scheduled for filing soon, signaling the company’s dedication to regaining compliance. This proactive approach illustrates Celularity's commitment to remedy the situation and strengthen its position.
CEO’s Perspective on Current Challenges
Robert J. Hariri, MD, PhD, Celularity's Chairman and CEO, addressed the situation candidly, acknowledging that many companies in the regenerative medicine field face financial pressures that can impact compliance. Hariri emphasized that these delays are not due to any accounting irregularities but stem from liquidity limitations and internal resource constraints. He expressed confidence in the company's future, particularly following the recent acquisition of the Rebound™ product, which is expected to enhance their financial stability and operational capacity.
Looking Ahead
As it navigates these challenges, Celularity continues to focus on meeting its reporting obligations. The company is diligently collaborating with its auditors to complete the necessary filings. This commitment is crucial for maintaining investor trust and confidence as they work through this phase. Regular updates will be provided as more developments unfold regarding their compliance efforts.
About Celularity Inc.
Celularity Inc. is at the forefront of regenerative medicine, specializing in the development and commercialization of innovative biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies. Their focus on therapies targeting aging-related diseases, including degenerative diseases and immune disorders, utilizes cutting-edge technologies such as mesenchymal-like adherent stromal cells (MLASCs), CAR T-cells, and both genetically modified and unmodified natural killer (NK) cells. They believe that the unique benefits of placenta-derived therapies can fulfill vital unmet needs for effective medical solutions.
Frequently Asked Questions
What led to Celularity's Nasdaq delisting notice?
Celularity received a delisting notice due to its failure to timely submit Forms 10-Q for specific periods, impacting its compliance with Nasdaq listing standards.
What steps is Celularity taking in response to the notice?
The company plans to appeal the determination before the Nasdaq Hearings Panel and is dedicated to regaining compliance through timely filings.
How does the delisting notice impact Celularity's stock?
Currently, there is no immediate effect, and Celularity's stock continues to trade on the Nasdaq under the symbols CELU and CELUW.
What is the significance of the Rebound™ product acquisition?
Acquiring the Rebound™ product is expected to significantly improve Celularity’s financial outlook and stabilize operations.
How can investors stay updated on Celularity's progress?
Investors can expect regular updates from the company on their compliance efforts and future strategic plans as the situation develops.
